Previous close | 17.24 |
Open | 17.06 |
Bid | 16.85 x 100 |
Ask | 16.97 x 100 |
Day's range | 16.91 - 17.23 |
52-week range | 8.39 - 22.19 |
Volume | |
Avg. volume | 220,124 |
Market cap | 515.876M |
Beta (5Y monthly) | 0.79 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.69 |
Earnings date | 13 May 2024 - 17 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 28.60 |
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the 23rd Annual Needham Virtual Healthcare Conference at 2:15 p.m. ET on Thursday, April 11, 2024. A live webcast w
Insiders who bought Celcuity Inc. ( NASDAQ:CELC ) stock in the last 12 months were richly rewarded last week. The...
Celcuity Inc. (NASDAQ:CELC) Q4 2023 Earnings Call Transcript March 27, 2024 Celcuity Inc. beats earnings expectations. Reported EPS is $-0.65, expectations were $-0.71. CELC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and gentlemen, and welcome to […]